Merck & Co Inc
NYSE:MRK

Watchlist Manager
Merck & Co Inc Logo
Merck & Co Inc
NYSE:MRK
Watchlist
Price: 99.45 USD 0.08% Market Closed
Market Cap: 251.6B USD
Have any thoughts about
Merck & Co Inc?
Write Note

Merck & Co Inc
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Merck & Co Inc
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Merck & Co Inc
NYSE:MRK
Net Issuance of Common Stock
-$1B
CAGR 3-Years
-12%
CAGR 5-Years
35%
CAGR 10-Years
14%
Johnson & Johnson
NYSE:JNJ
Net Issuance of Common Stock
-$1.5B
CAGR 3-Years
6%
CAGR 5-Years
31%
CAGR 10-Years
7%
Bristol-Myers Squibb Co
NYSE:BMY
Net Issuance of Common Stock
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pfizer Inc
NYSE:PFE
Net Issuance of Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zoetis Inc
NYSE:ZTS
Net Issuance of Common Stock
-$1.5B
CAGR 3-Years
-38%
CAGR 5-Years
-21%
CAGR 10-Years
N/A
Eli Lilly and Co
NYSE:LLY
Net Issuance of Common Stock
-$446.1m
CAGR 3-Years
4%
CAGR 5-Years
39%
CAGR 10-Years
8%
No Stocks Found

Merck & Co Inc
Glance View

Market Cap
251.8B USD
Industry
Pharmaceuticals
Economic Moat
Wide

Nestled in the heart of the pharmaceutical industry, Merck & Co., Inc. stands as a titan of innovation and healthcare. Established in 1891, the company has grown and evolved, driven by a mission to discover, develop, and provide innovative products and services that save and improve lives around the world. At the core of Merck’s operations is its commitment to research and development (R&D), which serves as the lifeblood of its product pipeline. With billions poured annually into R&D, Merck seeks to uncover new medical breakthroughs that address unmet medical needs across diverse therapeutic areas, such as oncology, vaccines, infectious diseases, and diabetes. This relentless pursuit of scientific advancement is not only a testament to Merck’s commitment to health but also a critical factor in maintaining its competitive edge in a crowded market. Merck's business model is elegantly straightforward yet highly structured. Primarily, the company's revenue streams are powered by the sales of prescription medications and vaccines that emerge from their exhaustive research efforts. Products like Keytruda, a cancer immunotherapy, and Gardasil, a vaccine for human papillomavirus, are standout performers, championing Merck's ability to penetrate high-value markets and secure regulatory approvals across the globe. Beyond the development and sale of pharmaceuticals, Merck generates additional revenue through collaborations and partnerships with other companies, leveraging co-development and marketing agreements to extend its reach. Underpinning Merck's financial model is its rigorous approach to cost management and strategic acquisitions, which bolster its robust product line-up and keep the engines of growth humming. This strategic orchestration ensures that while Merck fulfills its corporate mission, it also aligns with shareholder interests, reflecting a harmonious balance that has supported its storied legacy.

MRK Intrinsic Value
136.68 USD
Undervaluation 27%
Intrinsic Value
Price

See Also

What is Merck & Co Inc's Net Issuance of Common Stock?
Net Issuance of Common Stock
-1B USD

Based on the financial report for Sep 30, 2024, Merck & Co Inc's Net Issuance of Common Stock amounts to -1B USD.

What is Merck & Co Inc's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 10Y
14%

Over the last year, the Net Issuance of Common Stock growth was -83%. The average annual Net Issuance of Common Stock growth rates for Merck & Co Inc have been -12% over the past three years , 35% over the past five years , and 14% over the past ten years .

Back to Top